0Y
0YX.F Sysmex Corporation
- Market cap
- EUR 6.81B
- P/E
- 32.3x
- P/B
- 2.49x
- ROE
- 7.2%
- Dividend yield
- 2.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0YX.F undervalued?
Graham number0YX.F trades 89.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sysmex Corporation fundamental analysis
No fundamental analysis for Sysmex Corporation yet.
Sysmex Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sysmex Corporation
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochem…
Full company profileSysmex Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sysmex Corporation annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 250B | 282B | 294B | 302B | 305B | 364B | 411B | 462B | 509B | 500B | 523B |
| Gross Profit | 142B | 159B | 162B | 160B | 154B | 191B | 216B | 242B | 272B | 256B | 265B |
| Operating Income | 51.7B | 60.2B | 61.3B | 55.3B | 51.8B | 67.4B | 76.0B | 80.6B | 90.8B | 63.4B | 59.3B |
| EBITDA | - | 73.0B | 74.2B | 74.4B | 74.5B | 92.7B | 102B | 113B | 122B | 99.8B | 110B |
| Net Income | 40.5B | 39.1B | 41.2B | 34.8B | 33.1B | 44.1B | 45.8B | 49.6B | 53.7B | 35.5B | 34.8B |
| EPS | 194 | 187 | 197 | 167 | 158 | 211 | 219 | 80 | 86 | 57 | 57 |
| Balance Sheet | |||||||||||
| Total Assets | 280B | 322B | 347B | 389B | 427B | 484B | 531B | 619B | 665B | 708B | 747B |
| Total Liabilities | 69.6B | 80.5B | 81.6B | 111B | 119B | 135B | 143B | 186B | 201B | 202B | 260B |
| Shareholders' Equity | 209B | 241B | 264B | 278B | 308B | 348B | 388B | 432B | 464B | 505B | 486B |
| Cash & Short-term Investments | 57.9B | 61.4B | 51.1B | 56.6B | 66.5B | 73.8B | 69.5B | 75.5B | 89.6B | 84.1B | 114B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 32.8B | 52.2B | 44.7B | 53.2B | 58.8B | 58.7B | 68.8B | 63.9B | 88.2B | 73.8B | 142B |
| Capital Expenditure | 11.7B | 16.6B | 18.7B | 13.6B | 9.93B | 12.8B | 42.5B | 50.2B | 50.0B | 51.0B | 40.3B |
| Free Cash Flow | - | 26.5B | 15.8B | 26.7B | 33.0B | 26.7B | 26.3B | 13.7B | 38.3B | 22.9B | 102B |
| Ratios | |||||||||||
| ROE | 19.3% | 16.2% | 15.6% | 12.5% | 10.8% | 12.7% | 11.8% | 11.5% | 11.6% | 7.0% | 7.2% |
| ROA | 14.5% | 12.1% | 11.9% | 8.9% | 7.7% | 9.1% | 8.6% | 8.0% | 8.1% | 5.0% | 4.7% |
| Net Profit Margin | 16.2% | 13.9% | 14.0% | 11.5% | 10.9% | 12.1% | 11.2% | 10.8% | 10.6% | 7.1% | 6.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sysmex Corporation dividends
- Dividend yield
- 2.01%
- Forward dividend
- 0.23 EUR
- Payout ratio
- 63.3%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 22.4B | 36 | 63.3% |
| 2025 | JPY 18.1B | 29 | 33.7% |
| 2024 | JPY 17.6B | 28 | 35.4% |
| 2023 | JPY 16.5B | 79 | 36.1% |
| 2022 | JPY 15.3B | 73 | 34.6% |
| 2021 | JPY 15.0B | 72 | 45.4% |
| 2020 | EUR 15.0B | 72 | 43.2% |
| 2019 | EUR 14.6B | 70 | 35.5% |
| 2018 | EUR 12.5B | 60 | 32.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:1 on Mar 28, 2024.
Who owns Sysmex Corporation
- Insiders 27.34%
- Institutions 27.76%
- Public & others 44.89%
- Shares outstanding 602M
- Free float 512M
Sysmex Corporation company profile
- Company name
- Sysmex Corporation
- Ticker
- 0YX.F
- ISIN
- JP3351100007
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 10,861
- Fiscal year end
- March
- Address
- 1-5-1 Wakihama Kaigandori, Kobe, Japan, 651-0073
- Phone
- 81 78 265 0500
- Website
- sysmex.co.jp
About Sysmex Corporation
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing. The company also provides Caresphere, an ICT solution, which integrates and analyzes real time various data managed through testing instruments and clinical testing information systems, and supports the efficient operation of clinical laboratories; and involved in the medical robotics business. It serves products and services to medical institutions, clinical laboratories, animal hospitals, and research institutes. Sysmex Corporation has strategic alliance with Hologen to turn routine blood test data into clinical intelligence. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
Sysmex Corporation management
10- Mr. Hisashi IetsuguChairman of the Board & Group CEO · born 1949
- Mr. Iwane MatsuiPresident & Representative Director · born 1961
- Mr. Kensuke IizukaManaging Executive Officer, CFO & Director · born 1970
- Mr. Tomokazu YoshidaManaging Executive Officer, CTO & Director · born 1964
- Takashi HatakedaExecutive Officer & Executive VP of Corporate Communication Div.
- Mr. Frank BuescherSenior Executive Officer
- Mr. Kaoru AsanoRepresentative Director · born 1945
- Mr. Kenji TachibanaSenior Executive Officer, Senior MD & Director · born 1957
- Mr. Takashi OnoManaging Executive Officer & Director · born 1965
- Mr. Mitsuhisa KanagawaSenior Executive Officer